<DOC>
	<DOCNO>NCT00655824</DOCNO>
	<brief_summary>A 3-year open-label trial patient previously participate Trial Hx-CD20-403 fulfill eligibility criterion trial ( GEN413 ) . Th e primary purpose trial evaluate long-term effectiveness repeat course ( maximum 9 treatment course ) ofatumumab RA patient previously receive ofatumumab placebo Trial Hx-CD20-403 .</brief_summary>
	<brief_title>Long-term Efficacy Safety Repeated Ofatumumab Treatment Courses RA Patients Who Previously Received Ofatumumab Placebo Trial Hx-CD20-403</brief_title>
	<detailed_description>All patient fulfill eligibility criterion trial , initiate least one treatment course ofatumumab , depend subsequent worsen disease activity eligible receive treatment 156 week treatment period : maximum 8 treatment course give individualized time interval . The interval treatment course least 16 week last treatment course give later week 130 baseline ( Visit 2A ) . After treatment course patient attend next trial visit 8 week Infusion 1 , follow trial visit every 4 week Week 24 , subsequently every 8 week next treatment course . After complete Treatment Period withdraw Treatment Period prematurely patient follow every 12 week ( Follow-up Period ) CD19+ cell &amp; /or IgG level return baseline normal level .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Previously receive ofatumumab placebo Trial HxCD20403 . Patients methotrexate therapy ( 7.5 25 mg/week , p.o. , i.m. , and/or s.c. ) . Oral corticosteroid therapy ( ≤ 10 mg/day prednisolone equivalent ) . Active disease time screen define : 3 swollen joint ( 28 joint assess ) ≥ 3 tender joint ( 28 joint assess ) , DAS28≥3.2 ( base ESR ) Use DMARDs methotrexate exposure cell deplete therapy , include investigational compound &lt; 6 month prior Visit 2 A . Patients receive treatment nonmarketed drug substance within 4 week prior Visit 1 ( screen ) . Breast feeding woman woman positive pregnancy test Visit 1 ( screen ) . Received anticancer therapy , corticosteroid ( intraarticular , i.m. , i.v . ) , live/attenuated vaccination , exposure cyclophosphamide , nitrogen mustard , chlorambucil alkylating agent &lt; 5 year prior screen . Past current malignancy , except Cervical carcinoma Stage 1B less , Noninvasive basal cell squamous cell skin carcinoma , Malignant melanoma complete response duration &gt; 10 year , cancer diagnosis complete response duration &gt; 5 year . Chronic ongoing active infectious disease require systemic treatment . Clinically significant cardiac disease , history significant cerebrovascular disease . Significant concurrent , uncontrolled medical condition , limit , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease Known suspect HIV positive , positive serology hepatitis B ( HB ) , positive test Hepatitis C , positive plasma white cell JC virus ( JCV ) PCR ( either compartment ) . A circulate IgG level &lt; low limit normal . Known hypersensitivity component investigational medicinal product . Patients know suspected able comply study protocol . Women child bear potential use adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>